Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above (cHL 001)

NCT05404945 is registered in ClinicalTrials.gov with University of Virginia as lead sponsor.

NCT NCT05404945
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05404945 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above (cHL 001)
Lead sponsor
University of Virginia
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 26, 2022
Completion date
October 3, 2027
Enrollment
24 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

classical hodgkin lymphoma